We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
Read MoreHide Full Article
Arcturus Therapeutics Holdings Inc. (ARCT - Free Report) announced that it has selected ARCT-032 as a development candidate for Cystic Fibrosis (CF), which is a progressive hereditary disease.
ARCT-032, based on the company’s proprietary LUNAR technology, is designed to result in the efficient expression of a functional Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein in the lungs.
Shares of the company have surged 329.7% compared with the industry’s growth of 7.4%.
ARCT-032 will utilize Arcturus LUNAR lipid-mediated aerosolized platform to deliver CFTR mRNA to the lungs. Per the company, ARCT-032 has the potential to address the root cause of CF lung disease, which is caused by the defective or missing CFTR protein.
According to the company, preclinical studies of ARCT-032, which is based on the company’s LUNAR technology, have demonstrated that the inhaled therapy has the potential to successfully deliver CFTR mRNA to airway epithelial cells, which could result in the re-establishment of normal CFTR function in the lungs of CF patients.
There are several other companies,which have products either developed or in development for the treatment of CF. Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has Kalydeco in its portfolio for CF. Another company, AzurRx , is evaluating MS1819 in combination with porcine enzyme replacement therapy (PERT) in two clinical programs examining MS1819 in a phase IIb CF monotherapy and a phase II CF combination approach.
Zacks Rank & A Stock to Consider
Arcturus currently carries a Zacks Rank #4 (Sell).
Aerpio’s loss per share estimates have narrowed from 15 cents to 14 cents for 2020 and from 63 cents to 57 cents for 2021 over the past 60 days. Share price of the company has increased 58.8% year to date.
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027. Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
Arcturus Therapeutics Holdings Inc. (ARCT - Free Report) announced that it has selected ARCT-032 as a development candidate for Cystic Fibrosis (CF), which is a progressive hereditary disease.
ARCT-032, based on the company’s proprietary LUNAR technology, is designed to result in the efficient expression of a functional Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein in the lungs.
Shares of the company have surged 329.7% compared with the industry’s growth of 7.4%.
ARCT-032 will utilize Arcturus LUNAR lipid-mediated aerosolized platform to deliver CFTR mRNA to the lungs. Per the company, ARCT-032 has the potential to address the root cause of CF lung disease, which is caused by the defective or missing CFTR protein.
According to the company, preclinical studies of ARCT-032, which is based on the company’s LUNAR technology, have demonstrated that the inhaled therapy has the potential to successfully deliver CFTR mRNA to airway epithelial cells, which could result in the re-establishment of normal CFTR function in the lungs of CF patients.
There are several other companies,which have products either developed or in development for the treatment of CF. Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has Kalydeco in its portfolio for CF. Another company, AzurRx , is evaluating MS1819 in combination with porcine enzyme replacement therapy (PERT) in two clinical programs examining MS1819 in a phase IIb CF monotherapy and a phase II CF combination approach.
Zacks Rank & A Stock to Consider
Arcturus currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the healthcare sector includes Aerpio Pharmaceuticals Ltd. , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aerpio’s loss per share estimates have narrowed from 15 cents to 14 cents for 2020 and from 63 cents to 57 cents for 2021 over the past 60 days. Share price of the company has increased 58.8% year to date.
Alcobra Ltd. Price
Alcobra Ltd. price | Alcobra Ltd. Quote
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027. Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>